أندروجين
| أندروجين | |
|---|---|
| صف عقاقير | |
 Testosterone, the major androgen | |
| مميزات الصف | |
| المرادفات | Androgenic hormone; Testoid |
| الاستخدام | Hypogonadism, transgender men, performance enhancement, bodybuilding, others |
| كود ATC | G03B |
| الهدف الحيوي | Androgen receptor, mARs (e.g., GPRC6A, others) |
| الوصلات الخارجية | |
| MeSH | D000728 |
| In Wikidata | |
أندروجين ( androgen ؛ من اليونانية andr-، جذع الكلمة التي تعني "رجل") هو أي هرمون ستيرويدي طبيعي أو اصطناعي ينظم تطور وصيانة السمات الذكرية في الفقاريات بالارتباط بـ androgen receptors.[1][2] This includes the embryological development of the primary male sex organs, and the development of male secondary sex characteristics at puberty. Androgens are synthesized in the testes, the ovaries, and the adrenal glands.
Androgens increase in both males and females during puberty.[3] The major androgen in males is testosterone.[4] Dihydrotestosterone (DHT) and androstenedione are of equal importance in male development.[4] DHT in utero causes differentiation of the penis, scrotum and prostate. In adulthood, DHT contributes to balding, prostate growth, and sebaceous gland activity.
Although androgens are commonly thought of only as male sex hormones, females also have them, but at lower levels: they function in libido and sexual arousal. Androgens are the precursors to estrogens in both men and women.
In addition to their role as natural hormones, androgens are used as medications; for information on androgens as medications, see the androgen replacement therapy and anabolic steroid articles.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
الأنواع والأمثلة
The main subset of androgens, known as adrenal androgens, is composed of 19-carbon steroids synthesized in the zona reticularis, the innermost layer of the adrenal cortex. Adrenal androgens function as weak steroids (though some are precursors), and the subset includes dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), androstenedione (A4), and androstenediol (A5).
Besides testosterone, other androgens include:
- Dehydroepiandrosterone (DHEA) is a steroid hormone produced in the adrenal cortex from cholesterol.[5] It is the primary precursor of both the androgen and estrogen sex hormones. DHEA is also called dehydroisoandrosterone or dehydroandrosterone.
- Androstenedione (A4) is an androgenic steroid produced by the testes, adrenal cortex, and ovaries. While androstenedione is converted metabolically to testosterone and other androgens, it is also the parent structure of estrone. Use of androstenedione as an athletic or bodybuilding supplement has been banned by the International Olympic Committee, as well as other sporting organizations.
- Androstenediol (A5) is a steroid metabolite of DHEA and the precursor to sex hormones testosterone and estradiol.
- Androsterone is a chemical byproduct created during the breakdown of androgens, or derived from progesterone, that also exerts minor masculinising effects, but with one-seventh the intensity of testosterone. It is found in approximately equal amounts in the plasma and urine of both males and females.
- Dihydrotestosterone (DHT) is a metabolite of testosterone, and a more potent androgen than testosterone in that it binds more strongly to androgen receptors. It is produced in the skin and reproductive tissue.
- A4 and testosterone can also have an extra hydroxyl (-OH) or keton (=O) group bound on position 11. In this case you can have 11-hydroxyandrostenedione, 11-ketoandrostenedione, 11-hydroxytestosterone, and 11-ketotestosterone. The latter has the same biological activity as testosterone[6] and, therefore, these are also very important in healthy individals and patients with diseases like, congenital adrenal hyperplasia, polycystic ovarian syndrome, or premature adrenarche.[6]
Determined by consideration of all biological assay methods (ح. 1970):[7]
Female ovarian and adrenal androgens
The ovaries and adrenal glands also produce androgens, but at much lower levels than the testes. Regarding the relative contributions of ovaries and adrenal glands to female androgen levels, in a study with six menstruating women the following observations have been made:[8]
- Adrenal contribution to peripheral T, DHT, A, DHEA and DHEA-S is relatively constant throughout the menstrual cycle.
- Ovarian contribution of peripheral T, A and DHEA-S reaches maximum levels at mid-cycle, whereas ovarian contribution to peripheral DHT and DHEA does not seem to be influenced by the menstrual cycle.
- Ovary and adrenal cortex contribute equally to peripheral T, DHT and A, with the exception that at mid-cycle ovarian contribution of peripheral A is twice that of the adrenal.
- Peripheral DHEA and DHEA-S are produced mainly in the adrenal cortex which provides 80% of DHEA and over 90% of DHEA-S.
| Androgen | Ovarian (%) (F, M, L) | Adrenal (%) |
|---|---|---|
| DHEA | 20 | 80 |
| DHEA-S | 4, 10, 4 | 90–96 |
| Androstenedione | 45, 70, 60 | 30–55 |
| Testosterone | 33, 60, 33 | 40–66 |
| DHT | 50 | 50 |
| F = early follicular, M = midcycle, L = late luteal phase. | ||
Biological function
Male prenatal development
Testes formation
During mammalian development, the gonads are at first capable of becoming either ovaries or testes.[9] In humans, starting at about week 4, the gonadal rudiments are present within the intermediate mesoderm adjacent to the developing kidneys. At about week 6, epithelial sex cords develop within the forming testes and incorporate the germ cells as they migrate into the gonads. In males, certain Y chromosome genes, particularly SRY, control development of the male phenotype, including conversion of the early bipotential gonad into testes. In males, the sex cords fully invade the developing gonads.
Androgen production
The mesoderm-derived epithelial cells of the sex cords in developing testes become the Sertoli cells, which will function to support sperm cell formation. A minor population of nonepithelial cells appear between the tubules by week 8 of human fetal development. These are Leydig cells. Soon after they differentiate, Leydig cells begin to produce androgens.
Androgen effects
The androgens function as paracrine hormones required by the Sertoli cells to support sperm production. They are also required for the masculinization of the developing male fetus (including penis and scrotum formation). Under the influence of androgens, remnants of the mesonephron, the Wolffian ducts, develop into the epididymis, vas deferens and seminal vesicles. This action of androgens is supported by a hormone from Sertoli cells, Müllerian inhibitory hormone (MIH), which prevents the embryonic Müllerian ducts from developing into fallopian tubes and other female reproductive tract tissues in male embryos. MIH and androgens cooperate to allow for movement of testes into the scrotum.
Early regulation
Before the production of the pituitary hormone luteinizing hormone (LH) by the embryo starting at about weeks 11–12, human chorionic gonadotrophin (hCG) promotes the differentiation of Leydig cells and their production of androgens at week 8. Androgen action in target tissues often involves conversion of testosterone to 5α-dihydrotestosterone (DHT).
Male pubertal development
At the time of puberty, androgen levels increase dramatically in males, and androgens mediate the development of masculine secondary sexual characteristics as well as the activation of spermatogenesis and fertility and masculine behavioral changes such as increased sex drive. Masculine secondary sexual characteristics include androgenic hair, voice deepening, emergence of the Adam's apple, broadening of the shoulders, increased muscle mass, and penile growth.
Spermatogenesis
During puberty, androgen, LH and follicle stimulating hormone (FSH) production increase and the sex cords hollow out, forming the seminiferous tubules, and the germ cells start to differentiate into sperm. Throughout adulthood, androgens and FSH cooperatively act on Sertoli cells in the testes to support sperm production.[10] Exogenous androgen supplements can be used as a male contraceptive. Elevated androgen levels caused by use of androgen supplements can inhibit production of LH and block production of endogenous androgens by Leydig cells. Without the locally high levels of androgens in testes due to androgen production by Leydig cells, the seminiferous tubules can degenerate, resulting in infertility. For this reason, many transdermal androgen patches are applied to the scrotum.
Fat deposition
Males typically have less body fat than females. Recent results indicate androgens inhibit the ability of some fat cells to store lipids by blocking a signal transduction pathway that normally supports adipocyte function.[11] Also, androgens, but not estrogens, increase beta adrenergic receptors while decreasing alpha adrenergic receptors- which results in increased levels of epinephrine/ norepinephrine due to lack of alpha-2 receptor negative feedback and decreased fat accumulation due to epinephrine/ norepinephrine then acting on lipolysis-inducing beta receptors.
Muscle mass
Males typically have more skeletal muscle mass than females. Androgens promote the enlargement of skeletal muscle cells in a coordinated manner by acting on several cell types in skeletal muscle tissue.[12] One cell type, called the myoblast, conveys androgen receptors for generating muscle. Fusion of myoblasts generates myotubes, in a process linked to androgen receptor levels.[13] Higher androgen levels lead to increased expression of androgen receptor.
Brain
Circulating levels of androgens can influence human behavior because some neurons are sensitive to steroid hormones. Androgen levels have been implicated in the regulation of human aggression and libido. Indeed, androgens are capable of altering the structure of the brain in several species, including mice, rats, and primates, producing sex differences.[14] Although more recent studies showing the general mood of transgender men, who have undergone transgender hormone replacement therapy replacing estrogens with androgens, do not show any substantial long-term behavioral changes.[15][16][17]
Numerous reports have shown androgens alone are capable of altering the structure of the brain,[18] but identification of which alterations in neuroanatomy stem from androgens or estrogens is difficult, because of their potential for conversion.
Evidence from neurogenesis (formation of new neurons) studies on male rats has shown that the hippocampus is a useful brain region to examine when determining the effects of androgens on behavior. To examine neurogenesis, wild-type male rats were compared with male rats that had androgen insensitivity syndrome, a genetic difference resulting in complete or partial insensitivity to androgens and a lack of external male genitalia.
Neural injections of Bromodeoxyuridine (BrdU) were applied to males of both groups to test for neurogenesis. Analysis showed that testosterone and dihydrotestosterone regulated adult hippocampal neurogenesis (AHN). Adult hippocampal neurogenesis was regulated through the androgen receptor in the wild-type male rats, but not in the TMF male rats. To further test the role of activated androgen receptors on AHN, flutamide, an antiandrogen drug that competes with testosterone and dihydrotestosterone for androgen receptors, and dihydrotestosterone were administered to normal male rats. Dihydrotestosterone increased the number of BrdU cells, while flutamide inhibited these cells.
Moreover, estrogens had no effect. This research demonstrates how androgens can increase AHN.[19]
Researchers also examined how mild exercise affected androgen synthesis which in turn causes AHN activation of N-methyl-D-aspartate (NMDA) receptors.
NMDA induces a calcium flux that allows for synaptic plasticity which is crucial for AHN.
Researchers injected both orchidectomized (ORX) (castrated) and sham castrated male rats with BrdU to determine if the number of new cells was increased. They found that AHN in male rats is increased with mild exercise by boosting synthesis of dihydrotestosterone in the hippocampus.
Again it was noted that AHN was not increased via activation of the estrogen receptors.[20]
Androgen regulation decreases the likelihood of depression in males. In preadolescent male rats, neonatal rats treated with flutamide developed more depression-like symptoms compared to control rats.
Again BrdU was injected into both groups of rats in order to see if cells were multiplying in the living tissue. These results demonstrate how the organization of androgens has a positive effect on preadolescent hippocampal neurogenesis that may be linked with lower depression-like symptoms.[21]
Social isolation has a hindering effect in AHN whereas normal regulation of androgens increases AHN. A study using male rats showed that testosterone may block social isolation, which results in hippocampal neurogenesis reaching homeostasis—regulation that keeps internal conditions stable. A Brdu analysis showed that excess testosterone did not increase this blocking effect against social isolation; that is, the natural circulating levels of androgens cancel out the negative effects of social isolation on AHN.[22]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female-specific effects
Androgens have potential roles in relaxation of the myometrium via non-genomic, androgen receptor-independent pathways, preventing premature uterine contractions in pregnancy.[23]
Androgen insensitivity
Reduced ability of an XY-karyotype fetus to respond to androgens can result in one of several conditions, including infertility and several forms of intersex conditions.
Miscellaneous
Yolk androgen levels in certain birds have been positively correlated to social dominance later in life. See American coot.
Biological activity
Androgens bind to and activate androgen receptors (ARs) to mediate most of their biological effects.
Relative potency
Determined by consideration of all biological assay methods (ح. 1970):[7]
| Androgen | Potency (%) |
|---|---|
| Testosterone | 40 |
| 5α-Dihydrotestosterone (DHT) | 100 |
| Androstenediol | .0008 |
| Androstenedione | .04 |
| Dehydroepiandrosterone | .02 |
| Androsterone | .06 |
5α-Dihydrotestosterone (DHT) was 2.4 times more potent than testosterone at maintaining normal prostate weight and duct lumen mass (this is a measure of epithelial cell function stimulation). Whereas DHT was equally potent as testosterone at preventing prostate cell death after castration.[24] One of the 11-oxygenated androgens, namely 11-ketotestosterone, has the same potency as testosterone. [25]
Non-genomic actions
Androgens have also been found to signal through membrane androgen receptors, which are distinct from the classical nuclear androgen receptor.[26][27][28]
Biochemistry
Biosynthesis
Androgens are synthesized from cholesterol and are produced primarily in the gonads (testicles and ovaries) and also in the adrenal glands. The testicles produce a much higher quantity than the ovaries. Conversion of testosterone to the more potent DHT occurs in prostate gland, liver, brain and skin.
| جنس | هرمون الجنس | الطور التناسلي |
معدل الإنتاج بالدم |
معدل الإفراز بغدد التناسل |
معدل الإزالة الأيضي |
النطاق المرجعي (مستويات المصل) | |
|---|---|---|---|---|---|---|---|
| وحدات SI | وحدات بغير SI | ||||||
| رجال | Androstenedione | –
|
2.8 mg/day | 1.6 mg/day | 2200 L/day | 2.8–7.3 nmol/L | 80–210 ng/dL |
| تستوستيرون | –
|
6.5 mg/day | 6.2 mg/day | 950 L/day | 6.9–34.7 nmol/L | 200–1000 ng/dL | |
| إسترون | –
|
150 μg/day | 110 μg/day | 2050 L/day | 37–250 pmol/L | 10–70 pg/mL | |
| إستراديول | –
|
60 μg/day | 50 μg/day | 1600 L/day | <37–210 pmol/L | 10–57 pg/mL | |
| Estrone sulfate | –
|
80 μg/day | Insignificant | 167 L/day | 600–2500 pmol/L | 200–900 pg/mL | |
| نساء | Androstenedione | –
|
3.2 mg/day | 2.8 mg/day | 2000 L/day | 3.1–12.2 nmol/L | 89–350 ng/dL |
| تستوستيرون | –
|
190 μg/day | 60 μg/day | 500 L/day | 0.7–2.8 nmol/L | 20–81 ng/dL | |
| Estrone | Follicular phase | 110 μg/day | 80 μg/day | 2200 L/day | 110–400 pmol/L | 30–110 pg/mL | |
| Luteal phase | 260 μg/day | 150 μg/day | 2200 L/day | 310–660 pmol/L | 80–180 pg/mL | ||
| Postmenopause | 40 μg/day | Insignificant | 1610 L/day | 22–230 pmol/L | 6–60 pg/mL | ||
| إستراديول | Follicular phase | 90 μg/day | 80 μg/day | 1200 L/day | <37–360 pmol/L | 10–98 pg/mL | |
| Luteal phase | 250 μg/day | 240 μg/day | 1200 L/day | 699–1250 pmol/L | 190–341 pg/mL | ||
| Postmenopause | 6 μg/day | Insignificant | 910 L/day | <37–140 pmol/L | 10–38 pg/mL | ||
| Estrone sulfate | Follicular phase | 100 μg/day | Insignificant | 146 L/day | 700–3600 pmol/L | 250–1300 pg/mL | |
| Luteal phase | 180 μg/day | Insignificant | 146 L/day | 1100–7300 pmol/L | 400–2600 pg/mL | ||
| Progesterone | Follicular phase | 2 mg/day | 1.7 mg/day | 2100 L/day | 0.3–3 nmol/L | 0.1–0.9 ng/mL | |
| Luteal phase | 25 mg/day | 24 mg/day | 2100 L/day | 19–45 nmol/L | 6–14 ng/mL | ||
ملاحظات ومصادر
Notes: "The concentration of a steroid in the circulation is determined by the rate at which it is secreted from glands, the rate of metabolism of precursor or prehormones into the steroid, and the rate at which it is extracted by tissues and metabolized. The secretion rate of a steroid refers to the total secretion of the compound from a gland per unit time. Secretion rates have been assessed by sampling the venous effluent from a gland over time and subtracting out the arterial and peripheral venous hormone concentration. The metabolic clearance rate of a steroid is defined as the volume of blood that has been completely cleared of the hormone per unit time. The production rate of a steroid hormone refers to entry into the blood of the compound from all possible sources, including secretion from glands and conversion of prohormones into the steroid of interest. At steady state, the amount of hormone entering the blood from all sources will be equal to the rate at which it is being cleared (metabolic clearance rate) multiplied by blood concentration (production rate = metabolic clearance rate × concentration). If there is little contribution of prohormone metabolism to the circulating pool of steroid, then the production rate will approximate the secretion rate." Sources: See template. | |||||||
Metabolism
Androgens are metabolized mainly in the liver.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Medical uses
A low testosterone level (hypogonadism) in men may be treated with testosterone administration. Prostate cancer may be treated by removing the major source of testosterone: testicle removal (orchiectomy); or agents which block androgens from accessing their receptor: antiandrogens.
See also
References
- ^ Moini J (2015). Fundamental Pharmacology for Pharmacy Technicians. Cengage Learning. p. 338. ISBN 978-1-30-568615-1.
Androgen is the generic term for any natural or synthetic compound, usually a steroid hormone, which stimulates or controls the development of masculine characteristics by binding to androgen receptors.
- ^ Gylys BA, Wedding ME (2017). Medical Terminology Systems: A Body Systems Approach. F.A. Davis. p. 82. ISBN 978-0-80-365868-4.
Generic term for an agent (usually a hormone, such as testosterone or androsterone) that stimulates development of male characteristics.
- ^ "15 Ways To Get Rid of Pimples Overnight Natural". Fast Health Fitness. 2016-05-17.
- ^ أ ب Carlson N (22 January 2012). Physiology of Behavior. Reproductive Behavior. Vol. 11th edition. Pearson. p. 326. ISBN 978-0205239399.
- ^ "Androgens". DIAsource. Archived from the original on 8 August 2014. Retrieved 26 June 2013.
- ^ أ ب Adriaansen BP, Oude Alink SE, Swinkels DW, Schröder MA, Span PN, Sweep FC, et al. (January 2024). "Reference intervals for serum 11-oxygenated androgens in children". European Journal of Endocrinology. 190 (1): 96–103. doi:10.1093/ejendo/lvae008. PMID 38243909.
- ^ أ ب Briggs MH, Brotherton J (3 February 1970). Steroid Biochemistry and Pharmacology. London: Academic Press. ISBN 978-0-12-134650-8.
- ^ أ ب Abraham GE (August 1974). "Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle". The Journal of Clinical Endocrinology and Metabolism. 39 (2): 340–346. doi:10.1210/jcem-39-2-340. PMID 4278727.
- ^ Gilbert SF (2000). Developmental Biology (6th ed.). Sunderland, Massachusetts: Sinauer Associates. ISBN 978-0-87893-243-6.[صفحة مطلوبة]
- ^ Stephen Nussey, Saffron Whitehead (2001). Saffron A. Whitehead, Stephen Nussey (eds.). Endocrinology: an integrated approach. Oxford: British Institute of Organ Studies. ISBN 978-1-85996-252-7.[صفحة مطلوبة]
- ^ Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S (January 2006). "Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors". Endocrinology. 147 (1): 141–154. doi:10.1210/en.2004-1649. PMC 4417624. PMID 16210377.
- ^ Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S (October 2004). "Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment". The Journal of Clinical Endocrinology and Metabolism. 89 (10): 5245–5255. doi:10.1210/jc.2004-0084. PMID 15472231.
- ^ Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, et al. (March 2005). "Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene". The Journal of Biological Chemistry. 280 (9): 7786–7792. doi:10.1074/jbc.M413992200. PMID 15623502.
- ^ Cooke B, Hegstrom CD, Villeneuve LS, Breedlove SM (October 1998). "Sexual differentiation of the vertebrate brain: principles and mechanisms". Frontiers in Neuroendocrinology. 19 (4): 323–362. doi:10.1006/frne.1998.0171. PMID 9799588. S2CID 14372914.
- ^ Irwig MS (April 2017). "Testosterone therapy for transgender men". The Lancet. Diabetes & Endocrinology. 5 (4): 301–311. doi:10.1016/S2213-8587(16)00036-X. PMID 27084565.
- ^ Costantino A, Cerpolini S, Alvisi S, Morselli PG, Venturoli S, Meriggiola MC (14 February 2013). "A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery". Journal of Sex & Marital Therapy. 39 (4): 321–335. doi:10.1080/0092623X.2012.736920. PMID 23470169. S2CID 34943756.
- ^ Johnson JM, Nachtigall LB, Stern TA (1 November 2013). "The effect of testosterone levels on mood in men: a review". Psychosomatics. 54 (6): 509–514. doi:10.1016/j.psym.2013.06.018. PMID 24016385.
- ^ Zuloaga DG, Puts DA, Jordan CL, Breedlove SM (May 2008). "The role of androgen receptors in the masculinization of brain and behavior: what we've learned from the testicular feminization mutation". Hormones and Behavior. 53 (5): 613–626. doi:10.1016/j.yhbeh.2008.01.013. PMC 2706155. PMID 18374335.
- ^ Hamson DK, Wainwright SR, Taylor JR, Jones BA, Watson NV, Galea LA (September 2013). "Androgens increase survival of adult-born neurons in the dentate gyrus by an androgen receptor-dependent mechanism in male rats". Endocrinology. 154 (9): 3294–3304. doi:10.1210/en.2013-1129. hdl:2429/63213. PMID 23782943.
- ^ Okamoto M, Hojo Y, Inoue K, Matsui T, Kawato S, McEwen BS, Soya H (August 2012). "Mild exercise increases dihydrotestosterone in hippocampus providing evidence for androgenic mediation of neurogenesis". Proceedings of the National Academy of Sciences of the United States of America. 109 (32): 13100–13105. Bibcode:2012PNAS..10913100O. doi:10.1073/pnas.1210023109. PMC 3420174. PMID 22807478.
- ^ Zhang JM, Tonelli L, Regenold WT, McCarthy MM (August 2010). "Effects of neonatal flutamide treatment on hippocampal neurogenesis and synaptogenesis correlate with depression-like behaviors in preadolescent male rats". Neuroscience. 169 (1): 544–554. doi:10.1016/j.neuroscience.2010.03.029. PMC 3574794. PMID 20399256.
- ^ Spritzer MD, Ibler E, Inglis W, Curtis MG (November 2011). "Testosterone and social isolation influence adult neurogenesis in the dentate gyrus of male rats". Neuroscience. 195: 180–190. doi:10.1016/j.neuroscience.2011.08.034. PMC 3198792. PMID 21875652.
- ^ Makieva S, Saunders PT, Norman JE (2014). "Androgens in pregnancy: roles in parturition". Human Reproduction Update. 20 (4): 542–559. doi:10.1093/humupd/dmu008. PMC 4063701. PMID 24643344.
- ^ Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS (December 1996). "Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat". The Journal of Clinical Investigation. 98 (11): 2558–2563. doi:10.1172/JCI119074. PMC 507713. PMID 8958218.
- ^ Adriaansen BP, Oude Alink SE, Swinkels DW, Schröder MA, Span PN, Sweep FC, et al. (January 2024). "Reference intervals for serum 11-oxygenated androgens in children". European Journal of Endocrinology. 190 (1): 96–103. doi:10.1093/ejendo/lvae008. PMID 38243909.
- ^ Bennett NC, Gardiner RA, Hooper JD, Johnson DW, Gobe GC (June 2010). "Molecular cell biology of androgen receptor signalling". The International Journal of Biochemistry & Cell Biology. 42 (6): 813–827. doi:10.1016/j.biocel.2009.11.013. PMID 19931639.
- ^ Wang C, Liu Y, Cao JM (September 2014). "G protein-coupled receptors: extranuclear mediators for the non-genomic actions of steroids". International Journal of Molecular Sciences. 15 (9): 15412–15425. doi:10.3390/ijms150915412. PMC 4200746. PMID 25257522.
- ^ Lang F, Alevizopoulos K, Stournaras C (August 2013). "Targeting membrane androgen receptors in tumors". Expert Opinion on Therapeutic Targets. 17 (8): 951–963. doi:10.1517/14728222.2013.806491. PMID 23746222. S2CID 23918273.